Skip to main content

Table 4 Summary of current clinical trials targeting DNA methylation in melanoma

From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

Approach Phase Status Clinical trial identifier
Guadecitabine + ipilimumab for unresectable disease I Recruiting NCT02608437
Oral azacitidine + pembrolizumab for metastatic melanoma II Recruiting soon NCT02816021
Azacitidine + rInterferon alfa2b for stage III/IV unresectable I/II Completed, results not reported NCT00217542
Oral azacitidine bioequivalence study I Recruiting NCT02223052
Decitabine + vemurafenib + cobimetinib for resistant disease I/II Recruiting NCT01876641